Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
parietaria officinalis/antifúngic
L'enllaç es desa al porta-retalls
12 resultats
Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
The inhalation of Parietaria judaica pollen is a common cause of allergic respiratory diseases in the Mediterranean area. The objective of this study was to investigate the safety and clinical efficacy of a chemically modified (depigmented and glutaraldehyde-polymerized) vaccine of
Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Despite the use of conventional allergen-specific immunotherapy in clinical practice, more defined, efficient, and safer allergy vaccines are required.
OBJECTIVE
The aim of the study was to obtain hypoallergenic molecules by deleting B-cell epitopes, which could potentially be applied to
Purification of a novel aminopeptidase from the pollen of Parietaria judaica that alters epithelial integrity and degrades neuropeptides.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Parietaria judaica pollen is a common cause of pollinosis in the Mediterranean area.
OBJECTIVE
This study sought to purify and characterize the peptidase responsible for the majority of proteolytic activity present in the pollen extract of P judaica, and to investigate its contribution to
Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Sublingual-swallow immunotherapy was recently recognized in the World Health Organization Position Paper (Allergen immunotherapy: therapeutic vaccines for allergic diseases) "as a viable alternative to parenteral injection therapy to treat allergic diseases" in adults. More controlled
Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Parietaria pollen is one of the major causes of allergic reaction in southern Europe, affecting about 30% of all allergic patients in this area. Specific immunotherapy is the only treatment able to modify the natural outcome of the disease by restoring a normal immunity against allergens. The
Par j 1 and Par j 2, the major allergens from Parietaria judaica pollen, have similar immunoglobulin E epitopes.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Parietaria judaica is the main cause of allergy in Mediterranean countries. The major allergens from P. judaica pollen, Par j 1 and Par j 2, have amino acid sequence identity of 45% and contain eight cysteine residues involved in disulphide bonds that compact the structure.
OBJECTIVE
The
Isolation, expression and immunological characterization of a calcium-binding protein from Parietaria pollen.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The diagnosis and therapy of allergic disorders are usually performed with crude extracts which are a heterogeneous mixture of proteins with different allergenic potency. The knowledge of the allergenic composition is a key step for diagnostic and therapeutic options. Parietaria judaica pollen
Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A double-blind, placebo-controlled study was performed in order to confirm the safety, suitability, and efficacy of an alum-adsorbed Parietaria judaica-pollen allergoid, Allergovit, for allergen-specific immunotherapy. Parietaria pollen is an important cause of pollinosis, particularly in the
Allergic subjects express intercellular adhesion molecule--1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Allergic inflammation can be experimentally reproduced in vivo in humans, by means of the conjunctival provocation test with allergen. The allergen stimulation triggers an early clinical response and an almost simultaneous cellular infiltrate. Among the factors that can contribute to the
Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
The local (noninjection) routes of immunotherapy are presently regarded as viable therapeutic options for respiratory allergy, and their mechanisms of action are currently undergoing investigation.
OBJECTIVE
We evaluated the clinical efficacy of a preseasonal rush sublingual-swallow
[Pollinosis caused by Parietaria. Clinical observations in Northern Sardinia and botanical and allergic considerations on P. officinalis L. and P. judaica L. (P. diffusa Mert. and Koch)].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Botanical and allergological relations between two Parietaria species with greater pollinosic incidence, P. officinalis and P. judaica-P. diffusa, are examined: taxonomic and morphological aspects are discussed, and a key for their determination is proposed. Results of clinical-allergological survey
Medicinal plants used for cardiovascular diseases in Navarra and their validation from official sources.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
This paper provides significant ethnopharmacological information on plants used to treat cardiovascular diseases in Navarra, Spain.
METHODS
Information was collected using semi-structured ethnobotanical interviews with 667 informants (mean age 72; 55.47% women, 44.53% men) in 265
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
